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ABSTRACT
Despite many European Union (EU) conferences on ﬁghting microbial resistance, rates of resistance in
Europe continue to increase. Although research is catching up with discovery, the development of new
antimicrobials is threatened by economic factors, in particular the need for a return of investment via
high-volume sales. The EU should invest in independent research into the economic and business
aspects of antibiotic development. Multidisciplinary input from the ﬁelds of ﬁnance, law, marketing,
sociology and psychology will inform a broad agenda for change at the regulatory, academic and
commercial levels and identify new options for novel anti-infective research and development, as
recently recommended by the Science Academies of Europe (EASAC).
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The European Union’s (EU’s) attention to the
nightmare of antibacterial resistance will soon
reach a 10-year mark. While EU conferences
succeeded one another after ‘the microbial threat’
in 1998, rates of resistance to Neisseria gonorrhoeae
in Europe evolved in parallel with worldwide
increases [1], and pandrug-resistant Acinetobacter
baumannii spread over Europe [2,3]. The EU now
has its share of patients for whom the pre-
antibiotic era has returned. Meanwhile, in the
same period, only a few new antibiotics have been
registered. The process of drug discovery and
development takes, on average, 10–12 years, and
the costs exceed 800 million euro [4].
Why has the global development of new anti-
biotics been so unsuccessful? Scientiﬁc issues such
as the difﬁculty of identifying new classes of
antibacterial drugs, or the lack of novel research
between 1960 and 2000, are partly responsible, but
economic factors are also important. Innovative
research is now booming again, both in academic
institutions and in small companies [4,5], although
Europe is lagging somewhat behind [6]. The major
challenge for the near future is not so much
discovery, but the development of a safe drug
from promising products, which has up to now
been a task undertaken by large pharmaceutical
companies [3,7,8]. Economic factors are at the
heart of the matter. Multinational companies
increasingly depend on high-volume sales for
return of investment to shareholders, which
is contradictory to antibiotic policies [9]. Anti-
microbial drugs were banned from the agenda of
large companies because of the large number of
older off-patent compounds that were negatively
inﬂuencing drug pricing, a focus on chronic
disease and lifestyle drugs in the competition for
more secure proﬁts, and ﬁnally, the shrinking
market as a result of the success of policies
restricting the use of new antibiotics. The ﬂow of
new drugs, a fundamental societal need or a
common good, is driven by ﬁnancial proﬁt. This
constitutes a fundamental moral problem [10].
In addition, high sales undercut the beneﬁt of
antibacterial drugs, because high volumes of con-
sumption hasten the development of resistance.
Two EU expert groups have recently recom-
mended to the EU policy-makers that more be
invested in research to tackle antibacterial
resistance [11,12]. Up to now, the evidence base
to guide antibiotic prescribing has been
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astonishingly thin; the diagnosis of infection by
culture is slow, and distinguishing bacterial from
viral diseases is often difﬁcult in clinical practice.
Although the report from the European Technol-
ogy Assessment Group for Scientiﬁc Technology
Options Assessment (STOA) includes an interest-
ing analysis of the novel drug development crisis,
it recommends research to preserve the older
antibiotics, strategies to contain the spread of
resistance by improved surveillance and control
measures coordinated by the ECDC, the use of
rapid diagnostic tests, and efforts to reduce
overconsumption and inappropriate use [11].
EASAC experts, representing the science acade-
mies of the EU, state that these measures are
not sufﬁcient, and plead for research on new
drug development with a more rapid and ﬂexible
time-scale [12]. Will EU parliamentarians be
confused by this apparently contradictory advice?
Although both approaches make sense, abandon-
ing investment in new antibacterial drugs will
shift shortages to the coming decades.
Europe can learn from the US debate. Some of
the incentives for industry proposed by the
Infectious Diseases Society of America (IDSA) in
the white paper ‘Bad bugs no drugs’ [13] were
recently introduced into legislation concerning
bioterrorism after a ‘wildcard’ proposal was
abandoned [8]. Europe is following in the spirit
of other actions that have been proposed by the
IDSA. The European Commission supports risk
capital investment for small and medium-size
enterprises in the Competitiveness and Innova-
tion Framework Programme (2007–2013) [14]. The
Seventh Framework Programme for Research and
Technological Development FP7 will include
studies that address the economic burden of
resistance [11]. The Innovative Medicines Initia-
tive is one of the two Joint Technology Initiatives,
major new elements of FP7. Joint Technology
Initiatives, public/private partnerships involving
industry (EFPIA), the research community and
public authorities, are being set up for the ﬁrst
time at the European level, to pursue ambitious
common research objectives [15]. Finally, the
scientiﬁc committee of the European Medicines
Agency (EMEA), responding to the perception
that the regulatory process for new drugs has
become increasingly stringent, released a think-
tank document earlier this year that recom-
mended innovative regulatory approaches and
contained speciﬁc paragraphs on antibiotics [16].
I would like to launch an EU debate. If we must
accept that ﬁnancial incentives have been driving
scientiﬁc success in the context of public health in
our western societies in the past, Europe should
invest in novel independent economic research as
a counterpart to the business models that have
been unsuccessfully proposed to support industry
research and development (R&D) until now.
Following the proﬁt problem [17], we need the
proﬁt solution. Antibacterial drugs have acquired
many characteristics in common with orphan
drugs and the drugs used to treat neglected
diseases. Concerning the latter, an excellent
report, based on an empirical research approach
involving reviews of existing knowledge, with
recommendations from the London School of
Economics and Political Science, is available [9].
Besides such empirical approaches, experimental
approaches are needed to gain new insights into
the business aspect of novel antibiotic develop-
ment. Economic research should lead to policies
that match appropriate ﬁnancial incentives to
ﬁnancial motivations. Just as the behavioural
sciences are expected to shed light on the driving
forces behind antibiotic consumption, there is also
scope for multidisciplinary input into EU research
to inform a broad agenda for change and to
identify new options at the regulatory, academic
and commercial levels to support novel anti-
infective R&D, as recommended by EASAC. For
example, the next step in this endeavour could be
the preparation of an EU-funded call for scholar-
ships from EU business schools for PhD pro-
grammes concerning ﬁnancial economics or
management research involving a multidisciplin-
ary faculty from the ﬁelds of ﬁnance, law, mar-
keting, sociology and psychology. An interesting
topic for independent research in business ethics
would be to consider the motivation beyond
corporate social responsibility for antibacterial
drug development on the part of drug companies.
We need alternative business models for the
development of new antibacterial agents, not
without the preservation of the older antibiotics.
After years of reports and recommendations, it is
time for real actions that are paid for with euros,
not words. All EU hands to the EU pumps!
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